TNF and histoplasmosis: Etanercept was evaluated exclusively in an analysis of safety data from a multicenter study involving 2510 patients published in 2015, where there were no records of cases of histoplasmosis.[26] An analysis was performed excluding the 2 groups in which etanercept was the only TNF-α inhibitor used, and the incidence of histoplasmosis was 54.88 cases per 100,000 patients treated (95% CI 23.45–128.34, Figure 3).